公开(公告)号：US20130317055A1

公开(公告)日：2013-11-28

申请号：US13801660

申请日：2013-03-13

Applicant: ABBVIE INC.

Inventor： George M. HAIG ,  Jeffrey D. BAKER

IPC: A61K31/439

CPC classification number: A61K31/439 ,  A61K31/444 ,  A61K31/4748

Abstract: An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof.

Abstract translation: 一个实施方案涉及用于预防和治疗由烟碱乙酰胆碱受体介导的疾病和病症的神经元烟碱乙酰胆碱受体α7亚型的选择性激动剂及其药学上合适的盐，前药或代谢物及其使用方法。 另一个实施方案是向有需要的哺乳动物施用药学有效量的神经元烟碱乙酰胆碱受体α7亚型选择性激动剂，药学上合适的盐，前药或代谢物的方法。

公开(公告)号：US20130317054A1

公开(公告)日：2013-11-28

申请号：US13801276

申请日：2013-03-13

Applicant: ABBVIE INC.

Inventor： George M. HAIG ,  Jeffrey D. BAKER ,  Weining Z. Robieson

IPC: C07D471/08

CPC classification number: C07D471/08 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4748

Abstract: An embodiment relates to a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, a pharmaceutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a selective agonist of neuronal nicotinic acetylcholine receptor α7 subtype, or a pharmaceutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof.

Abstract translation: 一个实施方案涉及用于预防和治疗由烟碱乙酰胆碱受体介导的疾病和病症的神经元烟碱乙酰胆碱受体α7亚型的选择性激动剂及其药学上合适的盐，前药或代谢物及其使用方法。 另一个实施方案是向有需要的哺乳动物施用药学有效量的神经元烟碱乙酰胆碱受体α7亚型或其药学上合适的盐，前药或代谢物的选择性激动剂的方法。